Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest

Elizabeth Cairns / endpoints - Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study. The triple-G ...

AI Summary: Eli Lilly’s third‑generation GLP‑1 candidate reported Phase 3 data demonstrating significant weight loss and A1C reductions, with efficacy appearing comparable to existing therapies like Mounjaro. The results sharpen competition in the GLP‑1 market and raise questions about pricing, access and who gets first dibs on the next blockbuster injection.

• At clinics: GLP‑1 demand reshaping access, care and pricing (5)
• In labs: oral pills and novel GLP‑1 delivery approaches (4)
• On the ground: Lilly's triple‑G rivaling Mounjaro in trials (3)
• Other: clinical oddities, surgical implications and pipeline setbacks (5)

At clinics: GLP‑1 demand reshaping access, care and pricing

In labs: oral pills and novel GLP‑1 delivery approaches

On the ground: Lilly's triple‑G rivaling Mounjaro in trials

Other: clinical oddities, surgical implications and pipeline setbacks